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a panel of Spanish oncologists and from the literature. Unit costs
were derived from Spanish databases (€ March 2006). Annual
discount rate: 3.5% (costs and utilities). Sensitivity analyses for
subpopulations, 3 years results (Weibull and Loglogistic distrib-
utions) and probabilistic (Monte Carlo) were performed.
RESULTS: After 2 years more QALY per patient were obtained
with ERL (0.24) than with DOC (0.23) and BSC (0.18). No dif-
ferences versus PEM were observed. The total cost per patient
was lower with ERL (€17,838) than with DOC (€20,392; 
€−2554) or PEM (€27,317; €−9479) and higher than with BSC
(€8198; €+9640). ERL was the “dominant” treatment (more efﬁ-
cacy and lower costs) versus DOC and resulted in a cost saving
versus PEM. Additional cost per QALY or life year gained with
ERL versus BSC: €160,667 and €56,706, respectively. The 
sensitivity analysis conﬁrmed the robustness of the base case
analysis. If 1000 NSCLC patients were treated with ERL, the
annual saving for NHS (substitution rates: 5%–65%) would
range between €123,000–€1,600,000 (DOC replacement) and
€448,000–€5,831,000 (PEM replacement). CONCLUSIONS:
According to this model, advanced NSCLC treatment with ERL
is more cost-effective than with DOC and PEM, with savings for
the NHS.
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OBJECTIVES: Chronic cancer pain has a devastating impact on
quality of life. This leads to an increase in heathcare services uti-
lization. The objective of the present study is to estimate the cost-
efectiveness and cost-utility quotients of Fentanyl TTS treatment
related to SR oral Morphine or IR oral Morphine in patients
with moderate-severe chronic cancer pain. METHODS:
Designed from the perspective of the health care provider, with
a 12 weeks horizon and a pharmacoeconomic decision making
model (decision tree). Cost-effectiveness relationship estimates
was $15 per day of pain control (DPC) for Fentanyl TTS , $.3
per DPC for sustained-release Morphine and $6.4 per DPC for
immediate release Morphine. Cost-utility relationship estimates
was $23.1 per Quality Adjusted DPC (QALD) for Fentanyl TTS,
$18.9 per QALD for sustained-release Morphine and $53.6 per
QALD for immediate realease Morphine. This means that the
cost of a QALD when treating patients with Fentanyl TTS is
similar that patients treated with SR Morphine and less than half
of patients treated with IR Morphine. RESULTS: The incre-
mental cost-effectiveness relationship (ICER) for Fentanyl TTS
vs. SR Morphine was of $20,2 per extra DPC, while the ICER
for Fentanyl TTS vs. IR Morphine was $26.1 per extra QALD.
The incremental cost-utility relationship (ICUR) for Fentanyl
TTS vs. Sustained-release Morphine was $24.9 per extra QALD
and of $19.2 per extra QALD for Fentanyl TTS vs. IR Morphine.
The pharmacoeconomic model constructed for the analysis was
duly validated through a one way sensitivity analysis. 
CONCLUSIONS: We concluded, compared to oral Morphines,
Femtanyl TTS is a cost-effective choice for the treatment of mod-
erate-severe cancer pain. The present analysis allows to draw the
conclusion that the better efﬁciency of this new transdermal
pharmaceutical form of Fentanyl, is mainly due to an improve-
ment in qualtiy of life.
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OBJECTIVE: Dacarbazine is routinely used as the ﬁrst line treat-
ment of disseminated malignant melanoma with brain metas-
tases in Poland. A head-to-head randomized controlled trial
(RCT) showed a clinical superiority of fotemustine over dacar-
bazine in this indication. At the same time patients’ access to
many innovative medicines in Poland is limited because of bud-
getary constraints. Even if an innovative medicine is more effec-
tive and cost-effective, it is not applied since it is more expensive
for the health care budget. The main objective of this analysis is
to verify whether an administration of fotemustine is econom-
icly justiﬁed for the National Health Fund (NHF)—the public
payer in Poland. METHODS: A cost-minimization analysis was
carried out from the NHF point of view. Direct medical costs
were divided according to accounting standards into two groups:
cost of drugs and cost of hospitalization required in order to
administer the drugs. The majority of unit prices used in calcu-
lations were derived from the ofﬁcial price list of the Pomeran-
ian Sickness Fund (which is the NHF part now). Following
clinical standards and the length of the RCT the time horizon is
26 weeks. RESULTS: The cost of fotemustine administered to
one patient (€4700) is higher than the cost of dacarbazine (€676)
by €4024. The cost of hospitalization necessary to administer
dacarbazine amounts to €5884 and is higher than cost for fote-
mustine (€1284) by €4600. The total cost in fotemustine group
amounts to €598 and was lower than cost of dacarbazine
(€6560) by €576. CONCLUSION: Substitution of dacarbazine
with fotemustine in the treatment of disseminated malignant
melanoma with brain metastases is a good alternative not only
for Polish patients (as clinically better) but also for the Polish
NHF (as cost–saving). Ex. rate 1 € = 3.98 PLN.
PCN29
ECONOMIC ADVANTAGES AND TIMESAVING OF USING
OXALIPLATIN CONCENTRATED SOLUTION VERSUS
OXALIPLATIN LYOPHILISED POWDER FOR INFUSION
Favier B1, Spath HM2,Anhoury P3, Pacull A3
1Centre Leon Berard, Lyon, France, 2GRESAC, Lyon, France, 3IMS
Health Consulting & Services, Puteaux, France
OBJECTIVES: Oxaliplatin solution form is a new and safer for-
mulation of oxaliplatin avoiding the reconstitution step during
cytotoxic preparation. The main objective was to assess the eco-
nomic impact using oxaliplatin concentrated solution compared
with the lyophilised powder form from the hospital pharmacy
point of view. METHODS: Due to the equivalent efﬁcacy
between the 2 formulations, a cost-minimisation analysis with a
hospital perspective was performed comparing the solution
versus the powder. A single-centre observational study was con-
ducted in a French Cancer Centre. The cytotoxic preparations
were assessed using the powder in a ﬁrst time and the solution
form in a second time. The same staff member manipulated both
preparations in order to avoid any bias. Two independent
observers collected the results from the 30 manipulations. The
ﬁrst endpoint assessed was preparation time. Secondary endpoint
was overall cost associated with this preparation, which included
costs associated to preparation time, material and cytotoxic
waste management. RESULTS: The reconstitution step was
avoided using the solution form. The time saved with the solu-
tion form versus the lyophilised powder was 139 seconds per
preparation. The overall avoided cost represented €1.04 per
preparation using oxaliplatin solution form. This total cost could
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be broken up into three components: costs associated to the
preparation time (71%), material costs (27%) and the waste
management costs (2%). For 100 patients treated receiving 10
cycles of chemotherapy, this represents a total saving of €1040.
CONCLUSIONS: Using oxaliplatin concentrated solution form
represented a time saving and an economic beneﬁt for the hos-
pital pharmacist. In addition, this new solution form increases
the safety aspects by reducing risk of preparation errors and risk
of cytotoxic drug exposure for manipulators. It would be inter-
esting to conﬁrm those results in a multi-centric analysis.
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OBJECTIVES: OPTIMOX1 randomised study demonstrated
that FOLFOX7 with oxaliplatin stop-and-go could be safely
used and achieved the same efﬁcacy results as standard treatment
FOLFOX 4 in advanced colorectal cancer. The median progres-
sion free-survival and survival times were 9.0 and 19.3 months,
respectively in FOLFOX4 arm compared with 8.7 and 21.2
months, respectively in FOLFOX7 arm (p = not signiﬁcant).
FOLFOX 7 stop and go strategy was associated with reduced
risk of grade 3 to 4 toxicity [Tournigand, JCO 2006;24:394].
The main objective was to perform an economic evaluation of
FOLFOX7 stop-and-go compared with FOLFOX4 regimen in
advanced colorectal cancer. METHODS: A cost-minimisation
analysis has been conducted based on the efﬁcacy results of
OPTIMOX1 study. The perspective was that of the third party
payer and included only direct medical costs: chemotherapy, hos-
pitalisation and side effects management. The horizon time was
from inclusion until patient death. Sensitivity analyses were 
performed on drug costs and full/day hospitalisation rates.
RESULTS: Hospitalisation costs per patient were the main driver
for cost. Hospitalisation represented €6595 in FOLFOX7 arm
vs. €10,522 in FOLFOX4 arm reﬂecting the decrease of number
of hospitalisation days (p < 0.001). Chemotherapy costs per
patient were comparable in each treatment arm despite higher
doses of oxaliplatin with FOLFOX7 (€6870) compared to
FOLFOX4 (€7047) (p = 0.30). The cost of side effects manage-
ment appeared very low in both groups, compared to hospitali-
sation and drug costs with €271 and €382 (p = 0.11) for
FOLFOX4 and FOLFOX7 respectively. The mean total cost per
patient was higher in FOLFOX4 arm than in FOLFOX7 arm
with €17,841 versus €13,847 respectively (p < 0.001). CON-
CLUSION: The FOLFOX7 regimen with intermittent oxali-
platin treatment (stop-and-go) is cost saving compared with
FOLFOX4 regimen.
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OBJECTIVES: To compare costs of navelbine-cisplatine (PN)
versus gemcytabine-cisplatin (PG) recommended in non small
cell lung cancer (NSCLC) treatment in Poland. METHODS:
Data of health outcome, adverse event rates, speciﬁcation for
each regimen and the number of cycles derived from the pub-
lished head-to-head clinical trial (Martoni & co. European
Journal of Cancer 41, s.81–92, 2005). Only direct medical cost
were assessed such as diagnostic tests, cytostatics and additional
medication used and hospitalization (cost of blood tests and
antiemetics included). The payer’s perspective were chosen.
Information of value of health resources consumed were derived
from the medical valuation system used by National Fund of
Health in 2006. All cost were in polish zloty (in 2006: 1 euro =
3,95 zloty). RESULTS: Because there were no statistically sig-
niﬁcant differences in effectiveness between analyzed regimens,
the cost-minimisation analysis were performed. The average
total costs per patient was 10,452 zl for PN and 31,478 zl for
PG. However in both regimens the main part of total costs were
cost of gemcytabine (60%) or navelbine (55%), the nominal
value amount 5668 zl for navelbine and 18,860 zl for gem-
cytabine. In PG scheme 7% were cost of hospitalization and
4.5% cost of ADR treatment. In PN scheme 21,5% were cost of
hospitalization and 15.4% cost of ADR treatment. The high cost
of ADR management for PN were caused by cost of neutrope-
nia treatment. CONCLUSIONS: Despite of high percentage of
ADR management in PN, our analysis showed that total cost 
of chemotherapy with this scheme is three times less than
chemotherapy with PG. So the PN regimen should be recom-
mended as cost saving for patients with advanced NSCLC, spe-
cially as a palliative chemotherapy.
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OBJECTIVES: The oral formulation of ﬂudarabine phosphate is
equivalent to the IV formulation in terms of clinical efﬁcacy, in
previously untreated B-CLL. The objective of this evaluation is
to perform a cost minimization analysis. METHODS: To
conduct this evaluation the following parameters were consid-
ered: acquisition value of the IV and oral ﬂudarabine by the
public health system (PHS); resources consumption for IV ﬂu-
darabine application; toxicity proﬁle of the two presentations
based on literature data; adverse events management and their
resource consumption according to the Inca; PHS reimbursement
for the patients hospitalized with LCC; an index patient with
1.69 m2 body surface area and 60 years old; oral and IV ﬂu-
darabine dose of 40 mg/m2 and 25 mg/m2 respectively. The treat-
ment cost of a given adverse event was considered to be the same
irrespectively to the ﬂudarabine presentation. RESULTS:
Although oral ﬂudarabine presented a lower cost per mg in com-
parison to the IV formulation (R$9.85 vs. R$10.20) the total
drug cost for the whole treatment is greater for the oral formu-
lation than for IV (R$20,676.60 vs. R$15,300.00). However
considering that the administration cost per cycle of the IV 
formulation is R$956,80 the overall cost of IV ﬂudarabine
becomes higher than the oral formulation (R$22,150.78 vs.
R$23,160.31). The cost of the treatment of each considered
adverse event for oral and IV ﬂudarabine were respectively:
infection (339.72 vs. 519.99); neutropenia (962.79 vs. 1187.75),
anemia (106.02 vs. 222.74), diarrhea (11.97 vs. 0.00), nausea
(2.25 vs. 7.11) and thrombocytopenia (52.47 vs. 182.05).
Overall IV ﬂudarabine costs 4.56% more than its oral formula-
tion. CONCLUSIONS: This preliminary analysis shows that oral
ﬂudarabine has lower total cost per patient with similar efﬁcacy
to IV ﬂudarabine with lower adverse events and administration
costs. A cost effectiveness analysis should conﬁrm these promis-
ing data.
